Evidence map›Paper›PMID 39167179›Full record

ArticleAnnals of hematology2024

The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients.

Yutaka Shimazu, Junya Kanda, Teruhito Takakuwa, Yoshiyuki Onda, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Nobuhiko Uoshima, Yuji Shimura, Hirokazu Tanaka and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yutaka ShimazuDepartment of Hematology, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan. yshimazu@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-1604-7220
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
Teruhito TakakuwaDepartment of Hematology, Wakakusa Daiichi Hospital, Nara, Japan.
Yoshiyuki OndaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kentaro FukushimaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Masaaki HottaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Yuji ShimuraDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hirokazu TanakaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Kensuke OhtaHematology Ohta Clinic, Shinsaibashi, Japan.
Hirohiko ShibayamaDepartment of Hematology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Satoru KosugiDepartment of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Toyonaka, Japan.
Hideo YagiDepartment of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Satoshi YoshiharaDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya City, Japan.
Naoki HosenDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology, Graduate School of Medicine, Kyoto University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
Masayuki HinoDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Funding

Japan Society for the Promotion of Science JP24K11537
6 · The paper itself

Abstract

The prognosis for multiple myeloma (MM) patients has improved with the advent of new drugs, but the prognosis with renal impairment (RI) is poor. The choice of treatment in such cases is critical, but there are no set criteria. We examined the impact of RI on initial therapy in transplant-ineligible MM patients. We selected symptomatic MM patients who met the following criteria: age ≥ 65 years, fit, and ineligible for transplantation from the database. We analyzed the impact of age, treatment, International Staging System (ISS) stage, karyotype abnormalities, performance status, and estimated glomerular filtration rate (GFR < 50 or ≥ 50 ml/min/1.73m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsGlomerular Filtration RateMultiple MyelomaAgedAged, 80 and overAntibodies, MonoclonalBortezomibDexamethasoneFemaleHumansLenalidomideMaleMelphalanPrednisolonePrognosisRenal InsufficiencyAntibodies, MonoclonalBortezomibdaratumumabDexamethasoneLenalidomideMelphalanPrednisoloneMultiple myelomaOverall survivalPrognosisRenal dysfunctionTransplant-ineligible

Identifiers

PMID39167179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.